Table 2.
Univariate analysis of clinical features and laboratory parameters with histopathological response based on Huvos grading system.
| Features | Huvos response | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Poor | Good | CI 95% | |||||||
| n | % | n | % | p | RR | min | Max | ||
| Sex | Male | 28 | 70.0 | 12 | 30.0 | 0.110 | 0.800 | 0.621 | 1.030 |
| Female | 21 | 87.5 | 3 | 12.5 | |||||
|
| |||||||||
| Age | >20 years | 15 | 93.8 | 1 | 6.2 | 0.089∗ | 1.324 | 1.061 | 1.651 |
| ≤20 years | 34 | 70.8 | 14 | 29.2 | |||||
|
| |||||||||
| Length of complaint | >12 weeks | 40 | 85.1 | 7 | 14.9 | 0.016∗ | 1.461 | 1.011 | 2.556 |
| ≤12 weeks | 9 | 52.9 | 8 | 47.1 | |||||
|
| |||||||||
| Tumor site | Distal | 33 | 78.6 | 9 | 21.4 | 0.600 | 1.080 | 0.800 | 1.459 |
| Proximal | 16 | 72.7 | 6 | 27.3 | |||||
|
| |||||||||
| Tumor size (in diameter) | ≥10 cm | 41 | 82.0 | 9 | 18.0 | 0.075 | 1.435 | 0.895 | 2.300 |
| <10 cm | 8 | 57.1 | 6 | 42.9 | |||||
|
| |||||||||
| Postneoadjuvant chemotherapy tumor size | Enlarged | 45 | 88.2 | 6 | 11.8 | <0.001∗ | 2.868 | 1.261 | 6.521 |
| Shrunk | 4 | 30.8 | 9 | 69.2 | |||||
|
| |||||||||
| Staging | III | 18 | 94.7 | 1 | 5.3 | 0.028∗ | 1.375 | 1.100 | 1.719 |
| IIB | 31 | 68.9 | 14 | 31.1 | |||||
|
| |||||||||
| Metastasis | Present | 18 | 94.7 | 1 | 5.3 | 0.028∗ | 1.375 | 1.100 | 1.719 |
| Not identified | 31 | 68.9 | 14 | 31.1 | |||||
|
| |||||||||
| Pathological fracture | Present | 6 | 100.0 | 0 | 0.0 | 0.322∗ | 1.349 | 1.159 | 1.570 |
| Not identified | 43 | 74.1 | 15 | 13.6 | |||||
|
| |||||||||
| Preneoadjuvant chemotherapy ALP serum level | Increased | 24 | 82.8 | 5 | 17.2 | 0.578 | 1.073 | 0.840 | 1.371 |
| Normal | 27 | 77.1 | 8 | 22.9 | |||||
|
| |||||||||
| Preneoadjuvant chemotherapy LDH serum level | Increased | 50 | 79.4 | 13 | 20.6 | 1.000 | 0.794 | 0.700 | 0.900 |
| Normal | 1 | 100.0 | 0 | 0.0 | |||||
|
| |||||||||
| Postneoadjuvant chemotherapy ALP serum level | Increased | 19 | 79.2 | 5 | 20.8 | 0.703 | 1.056 | 0.804 | 1.386 |
| Normal | 30 | 75.0 | 10 | 25.0 | |||||
|
| |||||||||
| Increase in postneoadjuvant chemotherapy ALP serum level | Increased | 18 | 90.0 | 2 | 10.0 | 0.117∗ | 1.277 | 1.004 | 1.625 |
| Decreased | 31 | 70.5 | 13 | 29.5 | |||||
|
| |||||||||
| Postneoadjuvant chemotherapy LDH serum level | Increased | 48 | 76.2 | 15 | 23.8 | 1.000∗ | 762 | 0.664 | 0.875 |
| Normal | 1 | 100.0 | 0 | 0.0 | |||||
|
| |||||||||
| Increase in postneoadjuvant chemotherapy LDH serum level | Increased | 26 | 78.8 | 7 | 21.2 | 0.338 | 1.145 | 865 | 1.515 |
| Decreased | 22 | 71.0 | 9 | 29.0 | |||||
|
| |||||||||
| Neoadjuvant chemotherapy number of cycles | <2 cycles | 4 | 80.0 | 1 | 20.0 | 1.000∗ | 1.049 | 0.662 | 1.663 |
| ≥2 cycles | 45 | 76.3 | 14 | 23.7 | |||||
|
| |||||||||
| Interval towards surgery postneoadjuvant chemotherapy | >4 weeks | 27 | 25.3 | 6 | 7.7 | 0.306 | 1.153 | 0.874 | 1.520 |
| ≤4 weeks | 22 | 71.0 | 9 | 29.0 | |||||
|
| |||||||||
| Surgical procedure | Ablation | 21 | 77.8 | 6 | 22.2 | 0.845 | 1.028 | 0.783 | 1.349 |
| Salvage | 28 | 75.7 | 9 | 24.3 | |||||